15 March 2012 in The Journal of Rheumatology
Objective. To determine the association of use of tumor necrosis factor-α (TNF-α) inhibitors with differences in lipid levels in patients with rheumatoid arthritis (RA). Methods. We studied 807 patients with incident RA to compare differences in lipid levels in TNF-α inhibitor users versus nonusers, with adjustment for relevant covariables. Results. TNF-α inhibitor use was not associated with differences in levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), triglycerides, LDL:HDL, or TC:HDL compared to nonusers. Conclusion. Use of TNF-α inhibitor was not associated with differences in lipid levels in patients with RA.
13 May 2022 in Pharmacoepidemiology and Drug Safety
To describe the creation of prevalent new user (PNU) cohorts and compare the relative bias and computational efficiency of several alternative analytic and matching approaches in PNU studies. In a simulated cohort, we estimated the effect of a treatment of interest vs a comparator among those who switched to the treatment of interest using the originally proposed time-conditional propensity score (TCPS) matching, standardized morbidity ratio weighting (SMRW), disease risk scores (DRS), and several alternative propensity score matching approaches. For each analytic method, we compared the average RR (across 2000 replicates) to the known risk ratio (RR) of 1.00. SMRW and DRS yielded unbiased results (RR = 0.998 and 0.997, respectively). TCPS matching with replacement was also unbiased (RR = 0.999). TCPS matching without replacement was unbiased when matches were identified starting with patients with the shortest treatment history as initially proposed (RR = 0.999), but it resulted in very slight bias (RR = 0.983) when starting with patients with the longest treatment history. Similarly, creating a match pool without replacement starting with patients with the shortest treatment history yielded an unbiased estimate (RR = 0.997), but matching with the longest treatment history first resulted in substantial bias (RR = 0.903). The most biased strategy was matching after selecting one random comparator observation per individual that continued on the comparator (RR = 0.802). Multiple analytic methods can estimate treatment effects without bias in a PNU cohort. Still, researchers should be wary of introducing bias when selecting controls for complex matching strategies beyond the initially proposed TCPS.
18 December 2007 in Rheumatology
Objectives. Co-prescribing of proton pump inhibitors (PPIs) with non-selective NSAIDs (nsNSAIDs) is recommended in patients at risk of gastrointestinal (GI) events. This study estimated usage of PPI co-therapy among chronic nsNSAID users and determined factors associated with concurrent nsNSAID–PPI use. Methods. The retrospective study was based on the Intercontinental Marketing Services (IMS) Health UK MediPlus® database and included subjects ≥40 yrs of age who received their first oral nsNSAID prescription between July and December 2002 and who had ≥60 days of nsNSAID supply during the following year. Days with nsNSAID–PPI overlap were calculated and logistic regression was used to identify factors associated with nsNSAID–PPI overlap. A generalized linear model was used to assess the degree of association of GI risk factors with the nsNSAID–PPI overlap ratio among PPI users. Results. Of 16 344 patients included, 1586 received at least one PPI prescription. Among PPI users, PPIs were available on ∼50% of the days with nsNSAID therapy. After multivariate adjustment, age ≥65 yrs, history of any hospitalization and co-prescriptions for anti-coagulants or oral corticosteroids increased the odds of any nsNSAID–PPI overlap by 21–68%. Prior gastroprotective agent (GPA) use increased the odds of any PPI use during follow-up 16-fold and nsNSAID–PPI overlap 19-fold. Among PPI users, patients with prior use of any GPA had a 2.46 times higher nsNSAID–PPI overlap ratio. Conclusions. PPI utilization correlates poorly with nsNSAID use in the UK. GI safety of nsNSAID–PPI co-therapy observed in controlled trials may therefore not be achieved in clinical practice.